Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.27|
|52 Week High||AU$0.17|
|52 Week Low||AU$0.48|
|1 Month Change||-3.57%|
|3 Month Change||8.00%|
|1 Year Change||-3.57%|
|3 Year Change||145.46%|
|5 Year Change||50.00%|
|Change since IPO||35.00%|
Recent News & Updates
Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation
CEO Nina Webster has done a decent job of delivering relatively good performance at Dimerix Limited ( ASX:DXB...
Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
|DXB||AU Biotechs||AU Market|
Return vs Industry: DXB underperformed the Australian Biotechs industry which returned 1.7% over the past year.
Return vs Market: DXB underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: DXB is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: DXB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. The company develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; and DMX-700 that is in pre-clinical development for chronic obstructive pulmonary disease. The company was founded in 2004 and is headquartered in Fitzroy, Australia.
Dimerix Fundamentals Summary
|DXB fundamental statistics|
Is DXB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DXB income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.021|
|Net Profit Margin||-143.52%|
How did DXB perform over the long term?See historical performance and comparison
Is Dimerix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DXB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DXB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DXB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: DXB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DXB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DXB is overvalued based on its PB Ratio (55.3x) compared to the AU Biotechs industry average (4.8x).
How is Dimerix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dimerix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Dimerix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DXB is currently unprofitable.
Growing Profit Margin: DXB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DXB is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.
Accelerating Growth: Unable to compare DXB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: DXB has a negative Return on Equity (-433.89%), as it is currently unprofitable.
How is Dimerix's financial position?
Financial Position Analysis
Short Term Liabilities: DXB's short term assets (A$9.4M) exceed its short term liabilities (A$8.0M).
Long Term Liabilities: DXB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DXB's debt to equity ratio (343.9%) is considered high.
Reducing Debt: Insufficient data to determine if DXB's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DXB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DXB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 28.6% each year
What is Dimerix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DXB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DXB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DXB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DXB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DXB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Nina Webster, Ph D., BSc (Hons), M IP Law, MBA, has been Chief Executive Offer, Managing Director and Director of Dimerix Limited since August 27, 2018. Dr. Webster served as the Commercial Director of...
CEO Compensation Analysis
Compensation vs Market: Nina's total compensation ($USD304.93K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Nina's compensation has been consistent with company performance over the past year.
Experienced Board: DXB's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DXB insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.1%.
Dimerix Limited's employee growth, exchange listings and data sources
- Name: Dimerix Limited
- Ticker: DXB
- Exchange: ASX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$81.236m
- Shares outstanding: 300.87m
- Website: https://dimerix.com
- Dimerix Limited
- 425 Smith Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:26|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.